CO2024004755A2 - Formulaciones de polipéptidos enpp1 liofilizados y usos de estas - Google Patents
Formulaciones de polipéptidos enpp1 liofilizados y usos de estasInfo
- Publication number
- CO2024004755A2 CO2024004755A2 CONC2024/0004755A CO2024004755A CO2024004755A2 CO 2024004755 A2 CO2024004755 A2 CO 2024004755A2 CO 2024004755 A CO2024004755 A CO 2024004755A CO 2024004755 A2 CO2024004755 A2 CO 2024004755A2
- Authority
- CO
- Colombia
- Prior art keywords
- formulations
- enpp1
- lyophilized
- polypeptides
- deficiency
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 abstract 4
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 abstract 4
- 230000007812 deficiency Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000034970 Heterotopic Ossification Diseases 0.000 abstract 1
- 230000002308 calcification Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248303P | 2021-09-24 | 2021-09-24 | |
| PCT/US2022/076969 WO2023049864A1 (en) | 2021-09-24 | 2022-09-23 | Lyophilized enpp1 polypeptide formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024004755A2 true CO2024004755A2 (es) | 2024-05-10 |
Family
ID=85721287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0004755A CO2024004755A2 (es) | 2021-09-24 | 2024-04-16 | Formulaciones de polipéptidos enpp1 liofilizados y usos de estas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250073319A1 (https=) |
| EP (1) | EP4404980A4 (https=) |
| JP (1) | JP2024536821A (https=) |
| KR (1) | KR20240064707A (https=) |
| CN (1) | CN118215507A (https=) |
| AU (1) | AU2022353101A1 (https=) |
| CA (1) | CA3231858A1 (https=) |
| CO (1) | CO2024004755A2 (https=) |
| IL (1) | IL311578A (https=) |
| MX (1) | MX2024003506A (https=) |
| TW (1) | TW202330017A (https=) |
| WO (1) | WO2023049864A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4414028A3 (en) * | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| US12134790B2 (en) * | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| CA3126839A1 (en) * | 2019-01-18 | 2020-07-23 | Inozyme Pharma, Inc. | Treatment of diseases involving deficiency of enpp1 or enpp3 |
| CA3195071A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
-
2022
- 2022-09-23 CA CA3231858A patent/CA3231858A1/en active Pending
- 2022-09-23 WO PCT/US2022/076969 patent/WO2023049864A1/en not_active Ceased
- 2022-09-23 TW TW111136212A patent/TW202330017A/zh unknown
- 2022-09-23 EP EP22873898.5A patent/EP4404980A4/en active Pending
- 2022-09-23 JP JP2024518385A patent/JP2024536821A/ja active Pending
- 2022-09-23 AU AU2022353101A patent/AU2022353101A1/en active Pending
- 2022-09-23 MX MX2024003506A patent/MX2024003506A/es unknown
- 2022-09-23 IL IL311578A patent/IL311578A/en unknown
- 2022-09-23 KR KR1020247012631A patent/KR20240064707A/ko active Pending
- 2022-09-23 CN CN202280074276.7A patent/CN118215507A/zh active Pending
-
2024
- 2024-03-21 US US18/612,571 patent/US20250073319A1/en active Pending
- 2024-04-16 CO CONC2024/0004755A patent/CO2024004755A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240064707A (ko) | 2024-05-13 |
| TW202330017A (zh) | 2023-08-01 |
| JP2024536821A (ja) | 2024-10-08 |
| CA3231858A1 (en) | 2023-03-30 |
| US20250073319A1 (en) | 2025-03-06 |
| IL311578A (en) | 2024-05-01 |
| EP4404980A4 (en) | 2025-11-19 |
| MX2024003506A (es) | 2024-04-23 |
| EP4404980A1 (en) | 2024-07-31 |
| CN118215507A (zh) | 2024-06-18 |
| WO2023049864A1 (en) | 2023-03-30 |
| AU2022353101A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022002413A2 (es) | Composiciones y métodos para tratar la psoriasis y la dermatitis atópica usando prevotella histicola | |
| CO2019014682A2 (es) | Composiciones y métodos para enzimas de internalización | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MX2022004345A (es) | Construcciones de igf2 variantes. | |
| CO2023001489A2 (es) | Proceso de fraccionamiento de plasma usando plasma humano secado por atomización | |
| MX2021012894A (es) | Compuestos ciclicos de fosfato. | |
| ECSP10010372A (es) | Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| PE20190907A1 (es) | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas | |
| EP3818991A3 (en) | Compositions and methods for treating diseases | |
| CY1114792T1 (el) | Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης | |
| CL2021003045A1 (es) | Tratamiento de la disfunción sistólica | |
| MX2023009976A (es) | Compuestos de pladienolida y su uso. | |
| CL2024003870A1 (es) | Compuestos de degradación de wee1 y usos de los mismos | |
| CO2023000016A2 (es) | Proteínas enpp1 o enpp3 solubles y sus usos | |
| CO2025009104A2 (es) | Proteína triespecífica dirigida a trop2 para el tratamiento del cáncer | |
| EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
| CO2024004755A2 (es) | Formulaciones de polipéptidos enpp1 liofilizados y usos de estas | |
| ECSP23044970A (es) | Compuestos y composiciones de moléculas pequeñas | |
| EA202192964A1 (ru) | Комбинированная терапия | |
| CL2018001782A1 (es) | Metodos y composiciones para el tratamiento del sindrome de hunter. | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| CO2020014399A2 (es) | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida |